27.10
-0.35 (-1.26%)
| Penutupan Terdahulu | 27.44 |
| Jumlah Dagangan | 1,000,287 |
| Harga / Buku (P/B) | 11.00 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.97 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.80% |
| Nisbah Semasa (MRQ) | 5.13 |
| Aliran Tunai Operasi (OCF TTM) | -221.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -125.17 M |
| Pulangan Atas Aset (ROA TTM) | -47.45% |
| Pulangan Atas Ekuiti (ROE TTM) | -84.04% |
AISkor Stockmoo
| Nilai 30% | -0.8 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Masa 30% | -2.0 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Corak Lilin info | NA |
| Aliran bagi Tempoh Pegangan Anda info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Berita info | NA |
| Wang Pintar 20% | 3.5 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih +16.17% daripada saham dalam pemfailan 13F terkini: 199 pemegang menambah, 147 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -7.1% dari 31 Aug hingga 30 Oct 2026, 8.7 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Naik dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Tiada isyarat jelas daripada sokongan dan rintangan. info | |
| Skor Akhir | -0.13 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cogent Biosciences, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| COGT | - | - | - | 11.00 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
| SLGL | - | - | - | 3.80 |
| ACAD | - | - | - | 2.34 |
| CYTK | - | - | - | - |
|
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.04% |
| % Dimiliki oleh Institusi | 103.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fairmount Funds Management Llc | 30 Jun 2026 | 5,503,418 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 125.70%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 199 | 35,045,215 |
| Berkurang | 147 | 17,227,854 |
| Baharu | 57 | 13,674,570 |
| Dijual habis | 58 | 3,356,114 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 17,416,118 | 8.7 |
| 15 Oct 2026 | 19,661,566 | 8.9 |
| 30 Sep 2026 | 19,462,718 | 8.1 |
| 15 Sep 2026 | 18,126,492 | 11.8 |
| 31 Aug 2026 | 18,747,531 | 12.1 |
| 14 Aug 2026 | 18,411,111 | 8.9 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw Closer
Cogent Biosciences (COGT) reported widening third quarter losses and a busy regulatory calendar, posting a net loss of US$111.43 million as it approaches several FDA decisions on bezuclastinib. Cogent Biosciences’ share price has come under pressure in recent months, with the stock down about 30%… |
| 05 Nov 2026 | Yahoo Finance |
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of $791.1 million expected to fund operations into late 2028 WALTHAM, Mass. and BOULDER, Colo.… |
| 27 Oct 2026 | Yahoo Finance |
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim 3rd Annual… |
| 20 Oct 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
Three Regulatory Reviews, No Established Earnings Base Cogent Biosciences, Inc. (NASDAQ:COGT) has moved from proving bezuclastinib’s clinical activity to seeking regulatory approvals across distinct diseases. Its immediate valuation depends on a series of FDA decisions, starting with the November… |
| 25 Sep 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s… |
| 24 Sep 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased… |
| 24 Sep 2026 | Yahoo Finance |
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal… |
| 15 Sep 2026 | Yahoo Finance |
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent… |
Isyarat Terkini corak lilin dan silang EMA
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |